Young Plasma Infusions and Plasma Exchange in Anti-Aging

Understand

Overview

The idea that blood or plasma from a young organism could 'rejuvenate' an older one isn't new — experiments connecting the bloodstreams of two animals (parabiosis) were already conducted in the 19th century, and the topic returned to serious aging-biology research in the 2000s and 2010s, when teams including Irina and Michael Conboy's lab at UC Berkeley and Tony Wyss-Coray's group at Stanford published a series of well-designed mouse studies. The topic became even more popular culturally after 2016, when startups like Ambrosia began offering paid young-donor plasma infusions directly to consumers, inspired in part by — and, as it turned out, oversimplifying — these animal study results, a thread that also reached pop culture via an episode of 'Silicon Valley' and, later, public reports of entrepreneur Bryan Johnson's own experiments.

Understanding this topic requires separating three very different things that popular accounts often blur together: (1) mouse studies with heterochronic parabiosis, where the bloodstreams of a young and an old animal are surgically joined for weeks — the most solid, repeatedly replicated evidence line; (2) commercial single-dose infusions of young-donor plasma in humans, sold outright as an anti-aging therapy — a practice without solid efficacy evidence, which earned a formal FDA warning in 2019; and (3) therapeutic plasma exchange (TPE, plasmapheresis), a recognized medical procedure used for decades to treat specific autoimmune and hematologic diseases, originally unrelated to any anti-aging hypothesis, though sometimes invoked in this context because the mechanism of removing old plasma and replacing it with fresh fluid could theoretically remove pro-inflammatory factors that accumulate with age.

The mouse studies are real and repeatedly replicated, but their results are more complex than the simplified 'young blood rejuvenates' narrative suggests. Classic heterochronic parabiosis experiments showed that old mice joined to young ones via shared bloodstream showed improvement in some parameters — muscle regeneration, hippocampal neurogenesis, some organ function — but an equally well-documented, often omitted finding is that young mice joined to old ones showed accelerated aging of some tissues. This suggests that at least part of the effect may not be that young blood contains some magic rejuvenating factor, but that old blood contains factors accelerating aging, whose dilution (regardless of the dilution's source) may reverse part of the effect — a dilution hypothesis actively studied by the very same Conboy lab that ran the original experiments, as an alternative to the 'young rejuvenating factors' hypothesis.

Translating these animal results to humans is where the evidence base shrinks dramatically. There is no large, randomized, placebo-controlled clinical trial in humans confirming that infusing plasma from a young donor produces any measurable anti-aging effect. Available human data are small, mostly uncontrolled or only partially controlled safety and feasibility studies — some sponsored by the very companies selling this service, a significant conflict of interest warranting extra interpretive caution. Ambrosia, the most publicized commercial provider of this service, never published its results in a peer-reviewed journal — the publicly cited 'statistically significant biomarker improvements' come from the company's own marketing materials, not a scientific publication.

From a safety perspective, it's crucial not to separate young plasma infusion from the fact that it's a real medical procedure with real risk, not a wellness treatment comparable to massage or cryotherapy. Infusing any plasma, regardless of donor age, carries risk of allergic reactions (including rare but potentially life-threatening anaphylaxis), fluid overload in people with heart failure, and residual infection-transmission risk despite standard donor blood screening. These are known, documented complications of plasma transfusion as such — not hypothetical scenarios, but medically recognized risks that must be weighed regardless of the donor's age.

The people for whom this topic has practical relevance today are almost exclusively participants in supervised clinical trials evaluating the safety and feasibility of such infusions, conducted under institutional ethics board oversight. For everyone else — especially those considering paid, commercial infusions outside such oversight — the right summary is what the FDA itself stated in 2019: there's no evidence of clinical benefit, and the procedure carries real health risk that must be weighed consciously against a confirmed benefit of zero.

History of use

Parabiosis experiments — surgically joining two organisms into a shared bloodstream — date back to the 19th century and were originally used to study endocrine physiology, not aging. The first experiments joining young and old animals in an aging context were conducted as early as the 1950s and 1970s (including work by Clive McCay), but it was the work of the Conboy (Berkeley) and Wyss-Coray (Stanford) labs between 2005 and 2014, using modern molecular tools to probe specific mechanisms, that restored scientific credibility to this approach and sparked a new wave of interest. Commercialization followed quickly and, from a scientific standpoint, prematurely — companies like Ambrosia (founded 2016, closed after the 2019 FDA warning) began offering paid young-donor plasma infusions directly to consumers before any rigorous clinical trial confirmed such an effect in humans.